Abstract-The
binding of the Biphenyl-substituted piperazine derivative, [3H] GBR 12935, a selective dopamine uptake inhibitor, to the post-mortem human putamen was studied.
Inhibition curves by dopamine uptake inhibitors suggested the existence of two populations of [3H] GBR-12935 binding sites: one is potently inhibited by mazindol and/or nomifensine, and the second binding site is benz tropine and/or GBR 12909-sensitive.
In the human putamen, [3H] GBR-12935 labeled both these two distinct binding sites. The [3H] GBR-12935 binding displaced by mazindol was enriched in the mouse and rat striatum, but not in the cultured mouse neuroblastoma cell N1 E-115. The mazindol-sensitive [3H] GBR 12935 binding site increased in the presence of sodium and markedly decreased in the putamen from parkinsonians (45% of controls).
On the other hand, the [3H] GBR-12935 binding displaced by benztropine showed no sodium-dependent increase and was not decreased in the putamen from parkinsonians.
In the putamen from schizophrenics, the [3H] GBR-12935 binding did not significantly change in the density, while that displaced by mazindol tended to increase.
It is concluded that in the human putamen, [3H] GBR-12935 binds to two distinct sites. One site is partially sodium-dependent and appears to be associated with a high-affinity dopamine uptake system on dopaminergic nerve terminals. The second binding site shows no sodium-dependency and may be associated with a nondopaminergic and/or extraneuronal DA uptake system.
The principle mechanism for termination of the actions of synaptically released mono amines such as dopamine (DA), norepine phrine (NE) and serotonin has been con sidered to be their uptake into the presynaptic terminal. Selective transport mechanisms exist for each amine (1), but the elucidation of the DA uptake mechanisms has been limited because of the absence of selective ligands for labeling the DA transport complex. Recent studies using radiolabeled DA uptake blockers have described specific and satur able binding sites associated with the neuronal DA uptake system in the striatal membranes (2) (3) (4) (5) (6) (7) . Most of all these ligands have a poor selectivity for the DA transport complex compared with the norepinephrine (NE) uptake system. A series of diphenyl substituted piperazine derivatives (8) 
4 (3 phenyl propyl)-piperazine (GBR 12935) and GBR 12783, were introduced as ligands for labeling the DA transport complex with high selectivity and have provided a new tool for the study of DA transport system (9) (10) (11) .
Post-mortem human brains can provide useful information concerning human neuro pharmacology and pathology. Especially, the brains of patients with Parkinson's disease (PD) have been chosen as a 'natural' nigro striatal lesion model for studying dopamin ergic transmission. The present study charac terized the GBR-1 2935 binding sites in the post-mortem human putamen, as compared with those in the mouse and rat striatum, and the cultured mouse neuroblastoma N1 E 115 cells which take up DA (12) . We found that in the human putamen, two distinct GBR-12935 binding sites existed and showed different sodium-sensitivity.
One is partially sodium-dependent and decreased in the putamen from parkinsonians, which is related to the neuronal DA uptake. The second binding site, which also exists in the cultured cell N1 E-115, shows no sodium dependency and no alteration in the pu tamen from parkinsonians.
Furthermore, we studied the alteration of the binding levels in the putamen from schizophrenics in which abnormalities of the central dopaminergic transmission have been indicated. (13)) and histopathological evidence of depletion of pigmented nigral cells and the presence of Lewy bodies. The diagnosis for schizophrenia was based on DSM-III categories. All brain dissection was performed as described (14) . In some cases, for statistical analysis, groups have been matched for age and post-mortem delay.
Materials and Methods

Chemicals
Cell culture: Mouse neuroblastoma clone N1 E-1 15 cells were grown in Dulbecco's modified eagle medium (GIBCO) supple mented with 10% newborn calf serum. The cells were incubated at 370C in an atmos phere consisting of 10% C02 and 90% humidified air. The medium was changed at 2 day intervals. Cells were grown to con fluency prior to use.
Membrane preparation: The striatum from mouse and rat and the putamen from human brain were homogenized in 20 vol. of ice cold buffer (50 mM Tris-HCI, pH 7.4, 120 mM NaCI) with a Brinkmann Polytron (set ting at 7 for 1 5 sec). The homogenates were then centrifuged (for 20 min at 38,000xg) three times with resuspension of the inter mediate pellets in fresh buffer. Cultured cells were harvested mechanically with a rubber policeman, pelleted at 600xg for 10 min, in the above buffer, homogenated and cen trifuged as described above. The final pellets were stored at -80°C until assayed.
Binding Data are expressed as a percent of the total binding measured in the absence of each drug (mouse striatum, 3.1 pmol/mg protein; rat striatum, 3.5 pmol/mg protein; human putamen, 1.2 pmol/mg protein; N1 E-11 5 cells, 2.1 pmol/mg protein), and represent the mean of at least five experiments performed in triplicate, in which similar results were obtained. Fig. 1 . In the mouse and rat striatum, the rank order of potencies was: GBR 12909>mazindol>nomifensine> benztropine.
In the human putamen, the binding patterns of mazindol and nomifensine were different from those in the mouse and rat striatum, i.e., only 40-50% of the total [3H]GBR-12935 binding was inhibited at maximal concentration (0.1 mM) of mazindol and nomifensine, whereas these drugs in hibited the binding more effectively than benztropine at low concentration (1-10 nM). In contrast, GBR12909 and benztropine inhibited [3H] GBR-12935 binding with similar potencies in all tissues. The mazindol and/or nomifensine-insensitive site was dis placed by GBR 12909 and benztropine, and was enriched in the human putamen. This binding site also existed in the cultured cell N1 E-115 derived from mouse neuroblastoma which possesses a DA uptake system (12) .
Sodium dependency of [3H]GBR binding in human putamen:
Previous reports have shown that in the rat, [3H] GBR-12935 binding associated with a DA uptake system is dependent upon sodium, whereas that in some brain regions and tissues was inhibited by sodium (11) . The effect of sodium on [3H]GBR-12935 binding in the human putamen is shown in Fig. 2 
. When the [3H] GBR-12935
(1 nM) binding displaced by 5 i M mazindol was measured as a function of NaCI concentration, sodium-dependent increase of the binding was observed; the mazindol-sensitive specific binding was in creased by about 30% at the sodium con centration of 150 mM. This sodium dependency of the binding in the human putamen was not so marked as that of rat striatum (11) . In contrast, the specific bind ing of [3H] GBR-12935 to the human puta men was inhibited by increasing concen trations of sodium when 20 aM benztropine was used for determining the nonspecific binding. The specific [3H] GBR-12935 bind ing displaced by 20 uM benztropine also existed in N1 E-11 5 cell membranes and was inhibited by increasing concentrations of sodium (data not shown).
The [3H] GBR-12935 binding in the puta men from patients with Parkinson's disease and schizophrenia:
In the putamen from parkinsonians, the specific [3H]GBR-12935 (0.5 nM) binding displaced by 5 i€M mazindol was significantly lower (about 45% of control) than that in the putamen from controls (P<0.005) (Fig. 3) . The binding displaced by 5 uM mazindol in the putamen from schizophrenics tended to increase, al though the difference between the means was not statistically significant. When 20 /iM benztropine was employed to determine nonspecific binding, no significant difference was seen between the controls, parkinsonians and schizophrenics.
In schizophrenics, no significant changes of the binding levels was observed regardless of whether or not the patients had been on neuroleptics. The pos sible influences on the binding levels by age, the time from death to autopsy and the preservation time were neglected since no correlation was observed between the binding levels and these factors (data not shown). Furthermore, no significant changes in bind ing were found when the subjects were well matched for age, the time from death to autopsy and the preservation time. [3H]GBR 12935 binding site appeared to the lower in the human striatum than in the rat striatum, with a Kd value similar to that of the rat striatum.
We found that the two distinct [3H]GBR 12935 binding sites in the human putamen showed different sodium-sensitivity. It is generally accepted that the high-affinity DA uptake is sodium-dependent (1). Since the mazindol-sensitive [ 3H] GBR-12935 binding site showed a sodium-dependent increase, this site appears to be related to the high affinity DA transport system. The reduction of the mazindol-sensitive
[3H]GBR-12935 binding in the PD putamen and in the rat striatum lesioned with 6-hydroxydopamine supports this hypothesis (11, 17) .
The degree of decreased bindings in the PD putamen agrees well with the recent report by Janowsky et al. (17) . We obtained, however, rather lower binding levels as com pared with those reported by Janowsky et al. (17) , probably owing to the difference in membrane preparations. There is a noteworthy concept that it is necessary to lose 80-85% of the nigral neurons and to deplete the striatum of at least 80% of its dopamine content for frank symptoms of PD to appear (18 (19) . Thus, the heteroge neity of [3H] GBR-12935 binding sites in the human putamen may reflect different com partments of the DA uptake system in the brain. We cannot, however, exclude the pos sibility that the differences in the binding reflects the species differences in the charac teristics of the DA transporter system per se.
In the present study, we could not find apparent abnormalities of [3H] GBR-12935 binding in the putamen from schizophrenics. Although it has been widely accepted that there are abnormalities of the dopaminergic transmission in schizophrenia, our results sug gest that disturbances in the DA uptake system, if any, are not primarily associated with schizophrenic etiology and symp tomatology.
In conclusion, characteristics of [3H]GBR 12935 binding sites showed species differ ences, and there are two distinct [3H] GBR 12935 binding sites in the human putamen: one is partially sodium-dependent and po tently displaced by mazindol and nomi fensine, and the second binding site is inhibited by sodium and benztropine and/or is GBR 12909-sensitive.
The former is as sociated with the high-affinity DA uptake system on the dopaminergic nerve terminals, and the latter may be related mainly to non dopaminergic and/or extraneuronal compo nents.
